Sai-Hong IIgnatiusOuMDPhD

Oncology • Orange, CA

Professor, Medicine, University of California, Irvine College of Medicine

Join to view full profile

Dr. Ou is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ou's full profile

Already have an account?

Office
200 South Manchester Ave, Suite 400
Orange, CA 92868
Phone+1 714-456-5153

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
Duke University HospitalResidency, Internal Medicine, 1997 - 2000
University of Texas Southwestern Medical SchoolClass of 1997

Certifications & Licensure

CA State Medical License 2003 - 2027
AZ State Medical License 2008 - 2025
NC State Medical License 1999 - 2025
TX State Medical License 2010 - 2024
MA State Medical License 2000 - 2017
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Recruiting
Phase 1, Phase 2
Roles: Contact

Publications & Presentations

PubMed

Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review.
Yang Xia, Kaiwen Wang, Jing Zhao, Zhaohui Arter, Yongchang Zhang
Journal of Thoracic Oncology. 2024-11-30
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.
Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, Alessandra Bearz, Chia-Chi Lin
Journal of Thoracic Oncology. 2024-11-22
Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line tre...
Sai-Hong Ou, Hannah Kilvert, Jane Candlish, Ben Lee, Anna Polli
Lung Cancer. 2024-11-01

Lectures

Liquid Biopsy to Identify Actionable Genomic Alterations
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Medical Oncologist’s Perspective
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Characterization of 1,233 NSCLCs with non-del19/L858R EGFR mutations (EGFRm) using comprehensive genomic profiling (CGP).
2018 ASCO Annual Meeting - Chicago, Illinois - Chicago, Illinois- Chicago, Illinois - 06/3/2018
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all